Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1600-0773.1969.tb00506.x | DOI Listing |
ALTEX
December 2024
KaLy-Cell SAS, Plobsheim, France.
The effects of ten test chemicals towards thyroid sodium-iodide symporter (NIS), thyroid peroxidase (TPO), and deiodinases (DIOs) type I, II, and III were evaluated in in vitro rat and human systems and compared. Test chemicals known to directly affect TH levels in vivo were confirmed to effectively inhibit at least one of the tested in vitro endpoints, without significant disparities between species, and the tested compounds known to not affect thyroid function, were found ineffective. Interestingly, Iodide Transport Blocker 5, a potent non-competitive iodine uptake inhibitor, exhibited effects beyond direct NIS inhibition, by impacting NIS function through ATP depletion, and also inhibited TPO and DIO1/2 enzymes, although to a lesser extent.
View Article and Find Full Text PDFToxicol Rep
June 2024
Division of Medical Toxicology, Department of Emergency Medicine, UC San Diego Health, CA, USA.
Toxicol Appl Pharmacol
June 2024
FMC Corporation, 2929 Walnut St, Philadelphia, PA, USA. Electronic address:
Br J Pharmacol
July 2022
Pharmacometrics & Systems Pharmacology, Department of Pharmaceutical Technology and Chemistry, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain.
Background And Purpose: Acute intermittent porphyria (AIP) is a rare disease caused by a genetic mutation in the hepatic activity of the porphobilinogen-deaminase. We aimed to develop a mechanistic model of the enzymatic restoration effects of a novel therapy based on the administration of different formulations of recombinant human-PBGD (rhPBGD) linked to the ApoAI lipoprotein. This fusion protein circulates in blood, incorporating into HDL and penetrating hepatocytes.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!